We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Alder BioPharmaceuticals announced that its migraine drug eptinezumab succeeded in a late-stage trial for migraine – but shares immediately fell as investors raised concerns about a strong placebo effect.